BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 29614278)

  • 1. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of progestogens in women with preterm premature rupture of membranes.
    Di Sarno R; Raffone A; Saccone G
    Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Suhag A; Saccone G; Berghella V
    Am J Obstet Gynecol; 2015 Oct; 213(4):479-87. PubMed ID: 25797233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis.
    Boelig RC; Della Corte L; Ashoush S; McKenna D; Saccone G; Rajaram S; Berghella V
    Am J Obstet Gynecol MFM; 2019 Mar; 1(1):50-62. PubMed ID: 31172132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
    Langen ES; Sit A; Sherwin K; Lyell DJ; Blumenfeld YJ; El-Sayed YY
    Am J Perinatol; 2018 Jul; 35(8):779-784. PubMed ID: 29298456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
    EPPPIC Group
    Lancet; 2021 Mar; 397(10280):1183-1194. PubMed ID: 33773630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction within or after 12 hours of ≥36 weeks' prelabor rupture of membranes: a systematic review and meta-analysis.
    Bellussi F; Seidenari A; Juckett L; Di Mascio D; Berghella V
    Am J Obstet Gynecol MFM; 2021 Sep; 3(5):100425. PubMed ID: 34153513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic prophylaxis for term or near-term premature rupture of membranes: metaanalysis of randomized trials.
    Saccone G; Berghella V
    Am J Obstet Gynecol; 2015 May; 212(5):627.e1-9. PubMed ID: 25555659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Saccone G; Suhag A; Berghella V
    Am J Obstet Gynecol; 2015 Jul; 213(1):16-22. PubMed ID: 25659469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.
    Pergialiotis V; Bellos I; Hatziagelaki E; Antsaklis A; Loutradis D; Daskalakis G
    Am J Obstet Gynecol; 2019 Nov; 221(5):429-436.e5. PubMed ID: 31132340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.